Elite PharmaceuticalsELTP +1.50%55 Peter Lynch Fair Value is $0.57 as of Jul. 09, 2026, which is 10% below its 10-year median of 0.63. GuruFocus rates ELTP with a GF Score™ of 55/100 and a GF Value™ of $0.56 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 266 Drug Manufacturers companies, Elite Pharmaceuticals ranks better than 78.95% on this metric.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, Elite Pharmaceuticals's PEG is 1. Elite Pharmaceuticals's 5-Year TTM EBITDA Growth Rate is 22.71.
Elite Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $0.03. Therefore, the Peter Lynch Fair Value for today is $0.57.
The historical rank and industry rank for Elite Pharmaceuticals's Peter Lynch Fair Value or its related term are showing as below:
ELTP'
s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.62 Med: 0.63 Max: 0.65
Current: 0.65
During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of Elite Pharmaceuticals was 0.65. The lowest was 0.62. And the median was 0.63.
ELTP's Price-to-Peter-Lynch-Fair-Value is ranked better than 78.95% of 266
companies
in the Drug Manufacturers industry
Industry Median: 1.29
vs ELTP: 0.65
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
Elite Pharmaceuticals (OTCPK:ELTP) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 22.71 instead of 15 in this case.
Elite Pharmaceuticals's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
0.369
/
0.57
=
0.65
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elite Pharmaceuticals Peter Lynch Fair Value Related Terms
Elite Pharmaceuticals Peter Lynch Fair Value Historical Data
* Premium members only.
The historical data trend for Elite Pharmaceuticals's Peter Lynch Fair Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elite Pharmaceuticals Peter Lynch Fair Value Chart
ELTP vs EBS, NIKA, EOLS: Peter Lynch Fair Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Elite Pharmaceuticals's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elite Pharmaceuticals Price-to-Peter-Lynch-Fair-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Elite Pharmaceuticals's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where Elite Pharmaceuticals's Price-to-Peter-Lynch-Fair-Value falls into.
Elite Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) uses the latest annual data, which was $0.03.
* Note that for companies that do not have enough quarterly data to calculate the 5-Year TTM EBITDA Growth Rate, we use the annual data for the calculation.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
Elite Pharmaceuticals (ELTP) has a Peter Lynch Fair Value of $0.57 as of Jul. 09, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Elite Pharmaceuticals and its competitors. This is 10% below median its historical median of 0.63. Over the past decade, Elite Pharmaceuticals' Peter Lynch Fair Value has ranged from 0.62 to 0.65. According to the industry distribution chart, Elite Pharmaceuticals ranks #56 out of 266 companies in the Drug Manufacturers industry, placing it in the top 21.1%.
Is Elite Pharmaceuticals' Peter Lynch Fair Value too high?
Elite Pharmaceuticals' current Peter Lynch Fair Value of $0.57 is 10% below median its 10-year median of 0.63. Over the past 10 years, this metric has ranged from a low of 0.62 to a high of 0.65. The Drug Manufacturers industry median Peter Lynch Fair Value is 1.29. Elite Pharmaceuticals' value of $0.57 is 55.8% below this industry median. Based on the distribution chart, Elite Pharmaceuticals ranks #56 out of 266 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Elite Pharmaceuticals has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Elite Pharmaceuticals' Peter Lynch Fair Value compare to EBS and NIKA?
According to the Drug Manufacturers industry distribution chart, Elite Pharmaceuticals ranks #56 out of 266 companies for Peter Lynch Fair Value. This places Elite Pharmaceuticals in the top 21% of its industry — outperforming the majority of peers. The industry median Peter Lynch Fair Value is 1.29. Elite Pharmaceuticals' value of $0.57 is 55.8% below this benchmark. Historically, Elite Pharmaceuticals' own Peter Lynch Fair Value has ranged from 0.62 to 0.65 over the past decade. While the company's 10-year median is 0.63 vs. the industry median of 1.29, Elite Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Drug Manufacturers company?
The median Peter Lynch Fair Value among Drug Manufacturers companies is 1.29, based on 266 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Elite Pharmaceuticals's current Peter Lynch Fair Value of $0.57 is 55.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Elite Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Peter Lynch Fair Value is 1.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elite Pharmaceuticals's current Peter Lynch Fair Value is $0.57, which is 10% below median its own 10-year median of 0.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elite Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Elite Pharmaceuticals (ELTP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.56, compared to a current price of $0.37 — trading 34.1% below its estimated fair value. The current Peter Lynch Fair Value is $0.57, which is 10% below median its 10-year median of 0.63 and 55.8% below the Drug Manufacturers industry median of 1.29. Elite Pharmaceuticals' overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For Elite Pharmaceuticals (ELTP), the current Peter Lynch Fair Value is $0.57 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elite Pharmaceuticals (ELTP) Overvalued in 2026?
Based on GuruFocus' analysis, Elite Pharmaceuticals stock appears to be undervalued.
The current stock price of $0.37 is trading 34.1% below its estimated GF Value™ of $0.56.
GuruFocus considers Elite Pharmaceuticals to be Possible Value Trap.
Key valuation signals for ELTP:
Peter Lynch Fair Value: $0.57 (10% below median its 10-year median of 0.63)
GF Value™: $0.56 vs. price of $0.37 (34.1% below fair value)
Industry Position: 55.8% below the Drug Manufacturers median (#56 of 266)
No single metric tells the full story. See the ELTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
55GF Score
Get the complete analysis for ELTP
Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELTP has been successfully added to your 
